Oxford Industries, Inc. (OXM) Tops Q4 EPS by 5c, Will Pursue Sale of Ben Sherman
Get Alerts OXM Hot Sheet
Revenue Growth %: -4.2%
Financial Fact:
Diluted (in dollars per share): -0.1
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Oxford Industries, Inc. (NYSE: OXM) reported Q4 EPS of $1.08, $0.05 better than the analyst estimate of $1.03. Revenue for the quarter came in at $274.5 million versus the consensus estimate of $274.8 million.
The Company today announced that its Board of Directors has authorized the Company's management to pursue a sale of the Ben Sherman business. The Company has engaged Financo, Ltd. as its financial advisor to assist the Company in the process.
The Company expects to complete the sale of Ben Sherman during fiscal 2015. Therefore, the Company has excluded Ben Sherman operating results from the outlook for fiscal 2015 and from the fiscal 2014 results, as adjusted, that are presented for comparison. For reference, tables reconciling fiscal 2014 results from a GAAP basis to an adjusted basis are included at the end of this release.
Oxford Industries, Inc. sees FY2015 EPS of $3.45-$3.60, versus the consensus of $3.29. Oxford Industries, Inc. sees FY2015 revenue of $965-980 million, may not compare to $1.07 million.
Oxford Industries, Inc. sees FY2015 EPS of $1.15-$1.25, versus the consensus of $0.95. Oxford Industries, Inc. sees FY2015 revenue of $250-260 million, may not compare to consensus of $273.53 million.
For earnings history and earnings-related data on Oxford Industries, Inc. (OXM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Lemaitre Vascular (LMAT) Misses Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Corp. News, SpinoffsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share